Sign in Subscribe
COVID-19

GSK to Receive USD370m and Future Royalties in CureVac/BioNTech Settlement

Strategic Insights

— 1 min read

GSK will receive a significant payment as a result of the resolution of patent litigation between CureVac and BioNTech in the United States. The biopharmaceutical company will receive USD370m upfront, with a portion tied to an amendment reducing royalties GSK owes on potential future mRNA vaccines. Additionally, GSK will collect a 1% royalty on US sales of specific mRNA combination vaccines, and the company may receive further payments if the planned acquisition of CureVac by BioNTech closes. This agreement does not impact GSK's ongoing patent infringement litigation against Pfizer and BioNTech in the US and Europe.

Key Takeaways:

  • GSK will receive a USD370m upfront settlement as a result of the CureVac/BioNTech patent litigation resolution.
  • The settlement includes USD320m in cash and the remainder tied to an amendment reducing royalties GSK owes on potential future mRNA vaccines.
  • GSK will collect a 1% royalty on US sales of influenza, COVID-19, and related mRNA combination vaccines from the start of 2025.
  • If the planned acquisition of CureVac by BioNTech closes, GSK will receive an additional USD130m payment and a 1% royalty on future ex-US sales of the same products.
  • GSK will benefit from reduced milestones and a reduction in royalties payable in respect of its own mRNA vaccine sales outside of the United States.
  • The upfront payment will be recorded as other operating income in GSK's Q3 2025 results.
  • Royalty income will be included in total and core results going forward.

Statistics:

  • USD370m: The upfront settlement payment received by GSK.
  • USD320m: The cash component of the upfront settlement payment.
  • 1%: The royalty rate on US sales of influenza, COVID-19, and related mRNA combination vaccines.
  • 2025: The year when GSK will start collecting a 1% royalty on US sales of specified mRNA combination vaccines.
  • 16.6 million: The number of CureVac shares held by GSK.

Sources:

  • M2 PHARMA-August 8, 2025-GSK to receive USD370m and future royalties in CureVac/BioNTech settlement.

Read more